Opportunities this week:

This morning Ryanair reported Q1 FY26 results, that beat expectations across the board, we retain our price target at €28.00, with an unchanged recommendation of Overweight.
For GSK, following the FDA’s ODAC committee voting against the recommendation of Blenrep for treating Multiple Myeloma, we are lowering our price target to 1660p from 1820p and maintain our Overweight recommendation. (c. 22% upside)  
Following the deal announcement last Tuesday, we have changed our recommendation on the Dalata stock with a PT of €6.45 revised downward from our previous target of €6.93, with a Neutral position.